<?xml version="1.0" encoding="UTF-8"?>
<p>Patients should be (1) â‰¥20 years of age; (2) diagnosed with acute lymphocytic leukemia, acute myeloid leukemia, or myelodysplastic syndrome; and (3) eligible for allogeneic blood stem cell transplantation in accordance with the criteria of the local institution and the attending physician. Patients must also agree to comply with all study requirements. Patients should be excluded from the trial if they receive CHM from other sources.</p>
